Redeye provides an initial comment on the Q1 2025 report from Cheffelo, which was in line with annou...
Redeye returns with an update following AlzeCure's Q1 2025 earnings release, which aligned with our ...
Back to wallpaper growth in Q1 We lower '25e-'26e EBITA by 2-3% on Artscape-driven Q1 miss We reiter...
Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 proje...
Redeye comments on Combinedx’s Q1 report, showing solid profitability yet somewhat lower sales than ...
We downgrade our 2025-27 sales estimates by ~8%, owing to FX, while we downgrade 2025E-27E adjusted ...
Redeye updates its estimates and fair value range following CTEK’s Q1 results, which exceeded our ex...
Redeye provides an update on Scandinavian ChemoTech following the Q1 2025 report.
Redeye remains positive to Bredband2 despite its soft Q1 margins driven by growth efforts.
Redeye retains its view of Hanza following a Q1 report showing a relatively solid performance in a s...
Impressive margin lift in both segments, EBITA +6% vs.
Sales down 7% y-o-y, headwinds from weak end-markets persist Cut '25e-'27e sales by 4-2%, EBIT by SE...
Redeye provides its comment on Mendus’ Q1 2025 report.
Redeye comments on Invisio’s Q1-results which came in below our forecast with lower activity than ex...
Redeye interviewed Freemelt’s CEO, Daniel Gidlund, about the Q1 report and recently announced orders...
